June 12, 2025

New Releases from NCBI BookshelfToxicological Profile for 1,2-Dichloroethene.Toxicological Profile for 1,2-Dichloroethene.

The ATSDR toxicological profile succinctly characterizes the toxicology and adverse health effects information for the toxic substance described therein. Each […]

New Releases from NCBI BookshelfToxicological Profile for 1,2-Dichloroethene.Toxicological Profile for 1,2-Dichloroethene.

New Releases from NCBI BookshelfMelphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal).Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal).

New Releases from NCBI BookshelfDexamethasone intravitreal implant for treating diabetic macular oedema .Dexamethasone intravitreal implant for treating diabetic macular oedema .

New Releases from NCBI BookshelfAvalglucosidase alfa for treating Pompe disease.Avalglucosidase alfa for treating Pompe disease.

New Releases from NCBI BookshelfVedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal).Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal).

New Releases from NCBI BookshelfNivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma.Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma.

New Releases from NCBI BookshelfAvacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis.Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis.

New Releases from NCBI BookshelfBrolucizumab for treating diabetic macular oedema.Brolucizumab for treating diabetic macular oedema.

New Releases from NCBI BookshelfToxicological Profile for Naphthalene, 1-Methylnaphthalene, and 2-Methylnaphthalene.Toxicological Profile for Naphthalene, 1-Methylnaphthalene, and 2-Methylnaphthalene.

New Releases from NCBI BookshelfAtezolizumab for adjuvant treatment of resected non-small-cell lung cancer.Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer.

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.